BPG is committed to discovery and dissemination of knowledge
Retrospective Study
©The Author(s) 2025.
World J Hepatol. Dec 27, 2025; 17(12): 110726
Published online Dec 27, 2025. doi: 10.4254/wjh.v17.i12.110726
Table 2 Baseline investigations and treatment response of children receiving generic vs branded direct acting antivirals, n (%)
Variable
Patients who received Ledisbuvir (n = 43)
Patients who received Harvoni®(n = 73)
P value
Baseline investigations
Total bilirubin (mg/dL): Median (IQR)0.6 (0.3-0.9)0.4 (0.3-0.5)0.005
Direct bilirubin (mg/dL): Median (IQR)0.1 (0.1-0.2)0.1 (0.1-0.2)0.4
ALT (U/L): Median (IQR)51 (33.25-93.25)57 (43-101)0.4
AST (U/L): Median (IQR)51.5 (29.75-78)49 (36-66)0.
AP (U/L): Median (IQR)211 (158-294)239 (137-302)0.9
GGT (U/L): Median (IQR)40 (22.5-72.5)46 (23-87)0.7
Albumin (gm/dL), mean ± SD4.2 ± 0.54.1 ± 0.550.1
INR, mean ± SD1.12 ± 0.151.06 ± 0.070.02
Creatinine: Median (IQR)0.6 (0.5-0.87)0.6 (0.5-0.7)0.1
Degree of hepatic fibrosis by Fibroscan10.3
No/mild32 (74.4)59 (80.8)
Moderate/severe11 (25.6)13 (17.8)
End of treatment response43 (100)73 (100)NA
End of treatment investigations
Total bilirubin (mg/dL): Median (IQR)0.45 (0.3-0.9)0.4 (0.3-0.5)0.4
Direct bilirubin (mg/dL): Median (IQR)0.1 (0-0.2)0.1 (0.1-0.1)0.3
ALT (U/L): Median (IQR)25 (15-40)24 (18-32.5)0.7
AST (U/L): Median (IQR)26 (18-40)25 (20-31)0.7
AP (U/L): Median (IQR)198 (149-326)211 (142-285)0.6
GGT (U/L): Median (IQR)26 (19-36)20 (13-28)0.02
Albumin (gm/dL), mean ± SD4.2 ± 0.53.8 ± 0.50.002
INR, mean ± SD1.1 ± 0.21.08 ± 0.090.2
Creatinine: Median (IQR)0.65 (0.5-1)0.5 (0.4-0.6)0.002
Sustained virologic response43 (100)73 (100)NA


Write to the Help Desk